Skip to content

Blumenthal Calls For Criminal Investigation Into Meningitis Outbreak

(Washington, DC) – Today, in a letter to U.S. Attorney General Eric Holder, Senator Richard Blumenthal (D-Conn.) called for the U.S. Department of Justice to open a criminal investigation into the deadly meningitis outbreak linked to tainted drugs that has killed 14 people in 11 states. 

Blumenthal wrote, “In light of recent reports that the NECC may have flagrantly and blatantly violated both state and federal law, directly contributing to contamination of steroid products distributed nationally across state boundaries, I request that the Department of Justice begin a criminal investigation of the company, its officers and employees, and others who should be held accountable. Relevant to considering possible criminal enforcement are the horrific consequences of this tragedy − at least 169 victims, including 14 deaths, as well as thousands still at risk during the incubation period for fungal meningitis.”

Blumenthal continued, "Regardless of any possible ambiguity regarding regulatory authority, this company seems to have committed misconduct, potentially involving misrepresentation, fraud, and other criminality. One claim is that the NECC knowingly misled governmental authorities, as well as health care providers. Such misstatements may constitute mail or wire fraud under state and federal law, and other possible legal violations.”

Compounding is a process of combining, mixing, or altering ingredients in order to create a drug for a particular patient. Compounding pharmacies can make drugs for patients that are not typically available commercially, such as a drug made in a lower dosage for a child or a drug made without a dye or preservative for a patient with a specific allergy. Pharmacists that compound drugs have been subject to less federal regulation because they make drugs in response to a valid patient prescription, making the safety and efficacy trials required for drug manufacturing impractical and unnecessary. Compounding drugs without a patient prescription crosses the line from traditional compounding in limited quantities for a specific patient to mass production of drugs without proper FDA oversight. 
 
Below is a text of the letter Blumenthal sent to the Department of Justice:

October 11, 2012


The Honorable Eric H. Holder, Jr. 
The Attorney General
Washington, D.C.  20530

Dear Mr. Attorney General:

I know that you are as deeply troubled as I am by the tragic deaths and sicknesses caused by the apparent wrongdoing of the New England Compounding Center (NECC). I am concerned by the increasing amount of information available publicly and privately that indicates willful violations of law as well as basic standards of care by the NECC. 

In light of recent reports that the NECC may have flagrantly and blatantly violated both state and federal law, directly contributing to contamination of steroid products distributed nationally across state boundaries, I request that the Department of Justice begin a criminal investigation of the company, its officers and employees, and others who should be held accountable. Relevant to considering possible criminal enforcement are the horrific consequences of this tragedy − at least 169 victims, including 14 deaths, as well as thousands still at risk during the incubation period for fungal meningitis. The NECC’s apparent history of problems is also pertinent. In 2006, the FDA issued a warning to the pharmacy to change its practices, which seems to have been disregarded. In Massachusetts, each compounded medication requires an individual prescription. However, this requirement was allegedly ignored by the NECC.

Previously, I have called for new legislative authority, giving the FDA enhanced inspection and enforcement power that would help prevent such tragedies in the future. In some respects, compounding pharmacies like the NECC, which often make drugs in large quantities without specific individual prescriptions, engage in manufacturing that is effectively lacking in oversight. They operate in a regulatory black hole − a legal netherworld − without the regulation generally applied to pharmaceutical drug makers assuring that products are safe and effective. 

Regardless of any possible ambiguity regarding regulatory authority, this company seems to have committed misconduct, potentially involving misrepresentation, fraud, and other criminality. One claim is that the NECC knowingly misled governmental authorities, as well as health care providers. Such misstatements may constitute mail or wire fraud under state and federal law, and other possible legal violations.

I ask that the Department of Justice take the lead in coordinating investigations and prosecutions that may include state as well as federal authorities. Obviously, I have reached no conclusion as to criminal liability, but there seem to be sufficient, credible factual allegations and harm to warrant this request. I appreciate your interest and concern. 

Sincerely,

Richard Blumenthal
United States Senate